Biosimilarity Assessment

Authored by: Shein-Chung Chow , Fuyu Song

Encyclopedia of Biopharmaceutical Statistics

Print publication date:  August  2018
Online publication date:  August  2018

Print ISBN: 9781498733953
eBook ISBN: 9781351110273
Adobe ISBN:

10.1201/9781351110273-140000106

 Download Chapter

 

Abstract

In recent years, the assessment of biosimilarity between a proposed biosimilar product and an innovative biological product has attracted much attention since the passage of the Biologics Price Competition and Innovation Act in 2009. In this article, we provide an overview of regulatory requirements for review and approval of biosimilar products. Unlike the generic products, the development of biosimilar products is much more complicated because of fundamental differences in functional structures and manufacturing processes. As a result, the criteria and standard methods for the design and analysis of bioequivalence assessment of generic drug products may not be directly applicable to assessing biosimilarity of biosimilar products. In this article, we provide some scientific/statistical considerations for criteria, design, and analysis regarding the assessment of biosimilarity and drug interchangeability of biosimilar products. In addition, we discuss scientific and practical issues raised at the 2010 Food and Drug Administration (FDA) public hearing and the 2011 FDA public meeting on biosimilar products.

 Cite
Search for more...
Back to top

Use of cookies on this website

We are using cookies to provide statistics that help us give you the best experience of our site. You can find out more in our Privacy Policy. By continuing to use the site you are agreeing to our use of cookies.